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Abstract
Background: Our study analyses the main determinants of refusal or acceptance of the 2009 A/H1N1 vaccine in patients
with cystic fibrosis, a high-risk population for severe flu infection, usually very compliant for seasonal flu vaccine.
Methodology/Principal Findings: We conducted a qualitative study based on semi-structured interviews in 3 cystic fibrosis
referral centres in Paris, France. The study included 42 patients with cystic fibrosis: 24 who refused the vaccine and 18 who
were vaccinated. The two groups differed quite substantially in their perceptions of vaccine- and disease-related risks. Those
who refused the vaccine were motivated mainly by the fears it aroused and did not explicitly consider the 2009 A/H1N1 flu a
potentially severe disease. People who were vaccinated explained their choice, first and foremost, as intended to prevent
the flu’s potential consequences on respiratory cystic fibrosis disease. Moreover, they considered vaccination to be an
indirect collective prevention tool. Patients who refused the vaccine mentioned multiple, contradictory information sources
and did not appear to consider the recommendation of their local health care provider as predominant. On the contrary,
those who were vaccinated stated that they had based their decision solely on the clear and unequivocal advice of their
health care provider.
Conclusions/Significance: These results of our survey led us to formulate three main recommendations for improving
adhesion to new pandemic vaccines. (1) it appears necessary to reinforce patient education about the disease and its
specific risks, but also general population information about community immunity. (2) it is essential to disseminate a clear
and effective message about the safety of novel vaccines. (3) this message should be conveyed by local health care
providers, who should be involved in implementing immunization.
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Introduction
Vaccines are one of the most effective tools for preventing
infectious diseases, and high immunization coverage has led to
drastic declines in vaccine-preventable diseases. Nonetheless,
concern about adverse events associated with vaccines has risen
recently in the general population, resulting in an increase in the
number of people refusing vaccines and therefore the potential
resurgence of these diseases [1]. Recent events, specifically the
2009 A/H1N1 influenza (A/H1N1 hereafter), showed that this
concern is all the greater during a pandemic for which public
perception of vulnerability to the emerging infectious disease is
substantially counteracted by the fear that unsafe pharmaceuticals
might be rushed to market during the health crisis [2]. This is
further amplified by loss of public trust in the government’s
transparency and by the claims of anti-vaccine groups [3,4].
H1N1 is a novel influenza A virus that resulted in one of the
most widespread pandemics in recent history and a potential high
rate of mortality in subgroups of patients with chronic diseases [5].
This prompted the development of vaccines against this virus. As it
happens, the anti-A/H1N1 immunization strategy was a failure in
most industrialized countries [6–10]. Health authorities were then
blamed for mismanaging the preparedness efforts and for wasting
public funds [11].
Before this pandemic, little was known about population
attitudes towards new vaccines developed on an emergency basis
for such situations. Identifying the determinants that influenced
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overcome barriers to vaccination during future pandemics.
Analysing this phenomenon in high-risk populations, which
theoretically should have accepted the new vaccines, provides a
unique opportunity to gain insight into how risk perception (of
both pandemic effects and vaccination) predicts intention to be
vaccinated. This information could help to improve the efficacy of
future vaccination programmes.
Several studies have looked at various A/H1N1 vaccination
programmes [8–31]. All highlight strong public concern about the
safety of the new vaccines and the lower-than-anticipated severity
of the disease. Most of these studies, however, were cross-sectional,
before or during the pandemic, and based on quantitative
approaches. As risk assessment also depends on a set of
sociocultural factors that may change over time as the disease
pattern changes, it is highly improbable that any pre-established
list in quantitative questionnaires includes all possible reasons for
vaccine decisions. A qualitative approach provides a better
approach to understanding how vaccine-associated risk percep-
tions develop and how people construct their decisions for refusal
of the A/H1N1 vaccine and new vaccines in general [32]. The
efficacy of such studies can be increased by focusing on a
population with a homogeneous background, for example, a
shared disease, because patients have access to the same
information from their care providers. Response heterogeneity
and interpretation bias are thus lower.
In light of these considerations, we designed a study to analyse
the reasons for refusal of A/H1N1 vaccination during the 2009
pandemic. Our experimental approach used a qualitative analysis
and focused on a population at high risk of severe A/H1N1
infection: patients with cystic fibrosis (CF). Perceptions of vaccine-
and disease-related risks in patients that declined and accepted A/
H1N1 vaccination were studied. These results allowed us to
formulate recommendations to improve vaccination rates in new
pandemics and more generally to improve adhesion to new
vaccines.
Methods
1. Ethics statements
In November 2009, the ‘‘MucoFlu’’ research programme began
in the Paris region. This cohort study sought to evaluate the
clinical efficacy, immunogenicity, and tolerance of pandemic flu
vaccination in patients with CF (Clinical Trials.gov registration
number: NCT01499914). All patients followed in the CF centers
of the Parisian area received information about the pandemic A/
H1N1 flu, including a description of barrier measures, the main
characteristics of the infection, the particular susceptibility of CF
patients, the characteristics of vaccination against the A/H1N1
virus, and its benefits in the context of CF disease (Figure S1).
Patients were advised to be immunized as soon as possible. After
reception of this education leaflet by mail, all the patients were
contacted by the CF nursing staff for enrollment in the cohort and
vaccination. Written informed consent was obtained from all the
patients for the MucoFlu Research program. An additional sheet
was provided to inform on this specific anthropologic study. For
the children, written informed consent was obtained from the
parents but an information sheet was also provided to the children.
The protocol was conducted in accordance with the Declaration of
Helsinki and the relevant French statutes about biomedical
research and was approved by the Ethics Committee (‘‘Comite ´
de Protection des Personnes Ile-de-France III’’, Paris).
2. Study population
Vaccination adherence was assessed through a qualitative
survey in patients enrolled in the cohort. CF patients were
interviewed in June 2010, without any patient selection, during
regular medical appointments at 3 specialised centres for CF in
Paris (a pediatric centre, Necker Hospital; and two adult centres,
Cochin Hospital and the Centre Intercommunal de Creteil). This
method of recruitment from these cohorts of CF patients (300
children and 350 adults, respectively), during regularly scheduled
appointments and without selection to avoid any bias, provided
access to a fairly broad panel in terms of age and socio-professional
category. For the children younger than 15 years, the parents were
questioned because we assumed that the parents had made the
immunization decision.
In all, 42 persons were interviewed: 24 had refused the A/
H1N1 vaccine (refusers) (13 children aged from 6 to 18 years and
11 adults aged from 19 to 38 years), while 18 had been vaccinated
(accepters) between November 2009 and January 2010 (8 children
aged from 2 to 18 years and 10 adults aged from 19 to 55 years).
Since the sample size should be directed by the research question,
we stopped recruiting when new topics or factors stopped
emerging from additional interviews, as stated in Pope et al
[33]. There was no difference regarding socioeconomic charac-
teristics between the refusers and the accepters.
3. Data collection
One of the author interviewed the patients for between one and
two hours. All the interviews were fully recorded.
An exhaustive literature review allowed us to generate a list of
the most common themes related to the public’s acceptance of
novel vaccines. An interview outline guide, based on this list,
ensured systematic coverage of five main topics: (1) attitudes about
vaccination and vaccination history, (2) perception of the risks
related to the A/H1N1 vaccine and flu, (3) factors governing the
choice about the vaccine, (4) personal preventive measures against
the A/H1N1 flu other than the vaccine, and (5) information
sources and content. These in-depth interviews were semi-
structured to enable participants to talk in more detail about
their decision. Preplanned questions were asked, and open-ended
questions were formulated on the basis of participant responses.
The full interviews were transcribed from the recordings. The
transcripts were read by two authors several times to identify and
index themes and categories. All authors then participated in the
analysis, which combined thematic analysis with constant
comparison. The conceptual framework of grounded theory and
the entangled social logic approach were used to interpret the data
[34–37].
Results
1. Vaccination history of interviewees
In October 2009, 37 of the 42 interviewees had been regularly
vaccinated on an annual basis against seasonal flu (Table 1). Four
(two in the group that received the A/H1N1 vaccine and two in
the group that refused it) reported doing so irregularly, due either
to omission or indecision. Only one (in the group that received the
A/H1N1 vaccine) had never been vaccinated against seasonal flu.
His mother explained that he was still too young (6 years), but she
planned to have him vaccinated in the future.
The interviewees said that they were up to date with the other
vaccinations: BCG, diphtheria/tetanus/poliomyelitis, pertussis, H.
influenzae type b, measles/mumps/rubella, and meningococcal
meningitis type C for the youngest subjects. Thirty-four had
received pneumococcal vaccine, recommended for people with
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vaccine; the others stated that they did not remember. Only one of
those who had refused the A/H1N1 vaccine said he was opposed
to the HBV vaccine due to the controversy regarding the risk of
multiple sclerosis (Table 1).
Only four subjects, two in each group, reported a history of
vaccine-related adverse effects (Table 1). They described local or
moderate systemic reactions that they considered normal reactions
to vaccines, while 38 said they had never had a reaction to any
vaccine.
2. Perception of the risks related to the A/H1N1 vaccine
and reasons for refusing it
Of the 24 persons who refused the vaccine, 22 reported that the
main reason for their decision, far ahead of any other factor, was
fear about it. They did not ‘‘have confidence’’ in the vaccine,
which ‘‘scared’’ them. Above all, they mistrusted it because it was
a new pharmaceutical product developed in emergency circum-
stances. They considered the ‘‘hastily’’ developed vaccine
‘‘untrustworthy’’, not ‘‘100% safe’’. The clinical trials seemed
insufficient, the scientific safety data unreliable, and the available
experience about side effects nonexistent. Except for Guillain-
Barre ´ syndrome and multiple sclerosis, mentioned by some, most
interviewees were unclear about potential side effects. The vaccine
represented a vague threat with long-term health repercussions as
disturbing as they were unknown. This A/H1N1 vaccine was
allegedly responsible for ‘‘strange things’’, ‘‘serious repercussions
on future life’’, ‘‘unknown diseases’’, and contained ‘‘dangerous
substances’’. At the extreme end of the spectrum, some people
compared their fears with those aroused by other health events,
such as ‘‘mad cow disease’’ and ‘‘genetically modified food’’, and
particularly the specific fear of being considered simply a ‘‘guinea
pig’’. The two refusers who did not mention fears related to the
specific vaccine explained that they had not intentionally refused.
One said that his general health contraindicated vaccination and
the other that job constraints made it difficult for him to get to a
vaccination centre.
We also explored the subjects’ intentions in the event of another
outbreak of A/H1N1 flu. Of those who refused the vaccine during
the 2009 vaccination campaign, six thought they would refuse the
vaccine again if another epidemic occurred, five said they would
get it (they explained that they had been reassured and persuaded
by their health care providers), and 12 reported that they were still
undecided. In all cases, the recommendation of their health care
provider will be key: ‘‘Now that some time has passed since the
influenza A thing, and when we see all the to-do over nothing
much… if my doctor advises me to get vaccinated, I’ll get
vaccinated if it’s for the best’’.
Among the 18 vaccinated subjects, perceptions of the risk
related to this vaccine varied greatly. Twelve explained that they
had no specific fear of the vaccine; some said they had not heard
or did not remember hearing any information about side effects.
Others explained that they thought it was just another vaccine.
Still others mentioned that all vaccines can have side effects and
the messages about potential toxicity caused them no particular
concerns. Six patients mentioned fears of side effects and stated
that those came explicitly from media messages about these issues.
They added that the advice of their doctors had finally dissipated
their concerns.
There was no difference according to age regarding perception
of the risks related to the A/H1N1 vaccine.
3. Perception of the risks related to the A/H1N1 flu for
cystic fibrosis and reasons for H1N1 vaccine acceptance
Vaccination as direct prevention. The perception of the
risk related to the A/H1N1 flu varied widely in both groups, from
barely worrisome to very troubling. However, there were globally
inverse trends between the people who were vaccinated and those
who refused to be.
The A/H1N1 flu aroused moderate concern in 16 of the 24
people who refused the vaccine. Eleven of those stated that they
felt like ‘‘normal’’ people with respect to this flu (Figure S2). The
other eight said they perceived it as worrisome but not sufficiently
to convince them to accept the vaccination.
The vaccinated people all mentioned their particular vulnera-
bility to the A/H1N1 flu and infectious diseases in general (Figure
S2). Among them, 15 felt that influenza A was somewhat
worrisome to very troubling. Furthermore, all explained that they
had the A/H1N1 vaccine above all to protect themselves from the
A/H1N1 flu. This notion of prevention convinced six of them
immediately, while the 12 others relied on their doctors’
recommendations.
Table 1. Vaccination status according to A/H1N1 vaccination status.
2009 H1N1 vaccine
Refusers
(n=24)
Accepters
(n=18)
Vaccinated against seasonal influenza, 2009 Yes 22 15
Forgot 2 2
Refused 0 1
Vaccinated against pneumococci Yes 19 15
Does not remember 5 3
Refused 0 0
Vaccinated against hepatitis B virus Yes 20 13
Don’t remember 3 5
Refused 1 0
History of reactions to vaccines None 22 16
Mild 2 2
Serious 0 0
doi:10.1371/journal.pone.0034054.t001
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Vaccination as indirect collective prevention. In
questioning the interviewees about the decisions that members of
their family had made about the A/H1N1 vaccine, a new theme
emerged: the concept of vaccination as collective or group
prevention. Twelve of the 18 patients who had had the vaccine
stated that their entire family had been vaccinated to protect the
patient with CF against A/H1N1 flu. This action to prevent
disease inside the family group was mentioned by 7 of the 10
adults vaccinated who were questioned and 5 of the 8 families of
vaccinated children. Therefore, in that group, the collective
immunity aspect of the vaccine was clearly a necessary measure,
explicitly intended to protect others (Figure S3).
On the other hand, of the 24 persons who refused the A/H1N1
vaccine, only one said that her parents had been vaccinated to
protect her and her brother, but had not allowed them to be
vaccinated because of their concerns about side effects.
4. Personal preventive measures against the A/H1N1 flu
other than the vaccine as alternatives to the A/H1N1
vaccine
Barrier measures. Of the persons who refused the vaccine,
only 8 said they were concerned about the disease. All the patients
who refused the vaccine used ‘‘preventive’’ barrier measures
(Table 2). They described those protective measures as risk-free
alternatives and possibly even more effective than the vaccine.
More specifically, the measures ranged from simply increasing the
frequency of hand washing to voluntary strict isolation (including
withdrawing the child from school) and decreased or no use of
public transportation, avoiding contact, wearing a mask in public
places, etc.
On the contrary, those vaccinated against the A/H1N1 virus
reported barrier measures much less often. They maintained their
usual hygiene habits with varying degrees of reinforcement, all of
which were minor (increased frequency of hand washing, avoiding
contact, etc.).
Pharmaceutical alternatives. To protect themselves from
the flu pandemic, the people who refused the A/H1N1 vaccine
mentioned various ‘‘pharmaceutical alternatives’’ such as the
seasonal flu vaccine, oseltamivir and homeopathic remedies.
People who had the A/H1N1 vaccine almost never mentioned
such remedies (Table 2).
There was no difference according to age regarding preventive
measures implementation.
5. Information sources and content
Information sources. We questioned the interviewees about
their sources of information for the A/H1N1 flu and its vaccine.
The vast majority of those who refused the vaccine mentioned
multiple information sources, i.e., the media, people close to them
(family, friends, and colleagues), and health care providers. They
usually consulted several health care providers including doctors
and nurses from the CF centres, as well as doctors and other
medical professionals in private practice.
On the contrary, 15 of the persons who had the vaccine cited
one information source only, i.e. their physician from their CF
centre. More rarely, some also received information from other
local health care providers (other medical staff from the CF centre
or private practitioners, e.g., physicians, physiotherapists, and
nurses).
None of the interviewees reported the Internet to be their main
source of information about the A/H1N1 vaccine. Only four
people (two in each group) explicitly indicated that they had
searched for information about this subject on the Internet using
keyword searches with search engines or searches on the web site
of the patient association ‘‘Vaincre la mucovidose. No one
consulted forums, blogs, or social networks (e.g., Facebook) about
the vaccine.
Content of information. The information obtained was
perceived as conflicting by 22 of the 24 people who refused the
vaccine. They pointed first of all to the media, which gave voice to
a succession of viewpoints ranging from alarmist to trivializing.
The information in the media was deemed ‘‘too copious’’, ‘‘too
political’’, or ‘‘too polemical’’. At the same time, it provided
nothing ‘‘proven’’ because the ‘‘media are biased’’ and they are
only interested in ‘‘entertainment’’. This media fog and its parade
of those for and against the A/H1N1 vaccine, led the subjects in
the end to feel ‘‘a bit lost’’, ‘‘somewhat panicky’’, or to ‘‘no longer
really know what to think’’ (Figure S4). They stated that the
answers and advice from their various health care providers had
also been contradictory and tentative. More importantly, some
added that their doctor did not give them any clear instructions
about the vaccine, but left it up to them to decide whether or not
to be vaccinated. These persons largely had the impression they
were being left to their own devices by health care providers who
were shirking their advisory responsibility. They often did not take
kindly to this feeling of being ‘‘abandoned’’ and thus obliged to
make a decision about the A/H1N1 vaccine on their own, often
reluctantly.
Table 2. Measures of personal prevention.
2009 H1N1 vaccine
Refusal
(n=24)
Acceptance
(n=18)
Barrier measures Moderate 9 18
Substantial 15 0
Vaccination against seasonal influenza
2009
Protects against 2009 H1N1 flu 8 0
Does not protect against 2009 H1N1 flu 16 18
Oseltamivir Yes 5 1
No 19 17
Homeopathy Yes 2 0
No 22 24
doi:10.1371/journal.pone.0034054.t002
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information they received from their health care providers to be
clear and unequivocal. Sixteen said that the vaccine had been
clearly recommended to them. Only two reported several
conflicting sources and having had concerns. Similarly, those
who had the vaccine had no feeling of having been left to their
own devices about this decision. On the contrary, they all stated
that their decisions were based on clear and unambiguous medical
recommendations.
Patients in both groups observed a significant contrast between
the reality of the epidemic (knowing few or no people who had
actually had the A/H1N1 flu) and statements from the media and
political authorities, which were perceived as overly alarmist. The
media coverage of the erratic operation of the vaccination centres
– ranging from rare mobs to desertion by the public – contributed
to magnifying that impression of contradiction.
Discussion
Our study demonstrates that the main causes for refusal of the
vaccination for A/H1N1 were the perception of the risks linked to
a new vaccine compared to those linked to this specific type of flu,
which seemed benign and aroused only moderate concern in most
of the patients who refused. Instead, prevention measures
appeared to be reliable means to prevent infection. Information
sources did not help, and sometimes even hindered vaccination
acceptance, because they were perceived as contradictory and
unreliable.
People who were vaccinated explained their choice, first and
foremost, by the importance of prevention by vaccination,
particularly because of their disease. They relied on the advice
of their health practitioner. Moreover, they clearly associated the
preventive aspect of the vaccine with its altruistic dimension:
vaccination to protect others as well as themselves.
1. Strengths and limitations of the study
Our methodological position has a three-fold interest.
(1) Our study is the first to use a qualitative approach to better
analyse the motives for refusal. Such a methodology, based on in-
depth interviews allowing open questions during which people can
comment freely, allows access to the experiential contexts of the
interviewees, in which events unfold, risk perceptions develop, and
practices are guided [32,33,36]. This deepens the analysis of risk-
related perceptions and patient decision-making [38]. Moreover,
the patients were recruited and the interviews conducted one by
one as patients kept regularly scheduled appointments, without
any patient selection that could have led to bias. We stopped when
a point of data saturation was obtained for all of the topics
examined, which constitutes strong proof of qualitative rigor
[33,35]. Therefore, although this study does not have the
representative power of a randomised sample as in a quantitative
study, its qualitative methodology provided a very comprehensive
approach.
(2) We focused on one high risk disease group in one geographic
region. CF was used as a model because patients are better-
informed and educated about health issues than the general
population. As they manage their chronic disease, they gain a true
‘‘lay expertise’’ [39]. Moreover, these patients, all received the
same message from their CF doctors, supporting vaccination,
including the fact that influenza virus infections present a major
risk for them because they may exacerbate their respiratory disease
[40–43]. Most importantly, CF patients are generally very
compliant with seasonal flu vaccine, with coverage rates that
exceed 80% [44–47].
These specific characteristics thus serve to eliminate the
heterogeneity of samples taken from the general population.
Moreover, analysing the motives for refusal of the pandemic A/
H1N1 vaccine in this population highly aware of the dangers of A/
H1N1 infection allows us to focus in more detail on the reasons
specifically linked to the novelty of the vaccine. Finally, enrolment
of pediatric and adult patients allowed us to conclude that parents
of sick children do not behave differently than adult patients.
(3) Our interviews were conducted a few months after
vaccination ended in people who had faced the reality of a
pandemic. This contrasts to other studies, where subjects were
asked about their future intentions just as the pandemic began
[26–31]. While useful and scientifically legitimate, such prospec-
tive analyses involve a large degree of uncertainty, especially
because their data rely primarily on statements out of context. Our
data, based on real life experiences, allow us to evaluate the
development of the respondents’ behaviour. Moreover, patients in
this study stated that their experience and the motives for their
decision would determine their attitude in another H1N1
pandemic. The conclusions of this study are therefore useful to
illuminate the behaviour of patients in future pandemics [8,10]
2. Perceptions about A/H1N1 vaccine risks were the main
reason for refusing the new vaccine
We found a marked discrepancy in the assessment of vaccine-
related risks between refusers and accepters. The fear aroused by
the vaccine was the main reason for refusal. Two principal
explanations account for this fear of the vaccine: distrust of a new
vaccine manufactured on an emergency basis and concern about
its possible adverse effects. On this point, our results agree with the
conclusions of studies conducted in the general population
[8,9,17,19,26,27,29–31,48–50]
The fear aroused by the A/H1N1 flu did not however result in
uniform behaviours. The particular susceptibility to respiratory
infections of people with CF and the importance of prevention of
the A/H1N1 virus through vaccination were clear to the persons
who were vaccinated, for they indicated it as the main reason for
their decision. The patients who refused the vaccine described the
A/H1N1 flu as rather essentially untroubling, and they trivialized,
minimized, and even denied the notion of specific vulnerability in
CF patients [45,47,51]. On the other hand, most of them
implemented important barrier measures. This apparent contra-
diction suggests that A/H1N1 flu induced real worry in this group,
although not expressed explicitly but this was not sufficient to
convince them to be vaccinated. Clearly, the refusers shaped their
decision in a risk-benefit approach between a perception that new
vaccine equals lack of safety on the one hand and ignorance or
denial of their high-risk status on the other. Thus our findings
contrast with previous studies focused on specific high risk group,
namely pregnant women [15], patients with cardiovascular
diseases [18] or chronic respiratory diseases [52] that suggest a
strong correlation between the perception of high risk relative to
the A/H1N1 flu and the decision to be vaccinated.
3. Vaccination outlook: the altruistic attitude predicts
adherence to a new vaccine
Examining what we might call the ‘‘vaccination outlook’’ of the
interviewees, we did not find anti-vaccination attitudes in either
group, or exclusive adherence to alternative medicine, or any
history of serious vaccination reactions. On the contrary, the
interviewees, including those who refused the vaccine, very largely
adhered to vaccination principles and overwhelmingly follow
vaccination recommendations, including for seasonal flu.
Refusal of A/H1N1 Pandemic Vaccination
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vaccine does not directly correlate with the attitude toward
seasonal flu vaccination or, more generally, towards other
vaccinations. These results contrast with the findings of Seale
and Schwarzinger [26,27] regarding the association between a
positive attitude toward vaccination for the seasonal flu vaccine
and adherence to the A/H1N1 vaccine in the general population.
Our results go even farther. ‘‘Vaccination outlook’’ differed in
one essential point between persons who refused the A/H1N1
vaccine and those who took it. The community immunity
preventive function of vaccines and the altruistic act of being
vaccinated to protect others as well as oneself were dominant
notions in persons who took the vaccine and practically absent in
those who refused it. Therefore, our results suggest that the
altruistic principle of vaccination in the general population is a
factor that predicts adherence to a new vaccine. Similar results
were also shown in health care workers [20].
Thus, one of the main foundations of the refusal process for new
vaccines is not only mistrust of the vaccine itself but also the
disconnection of vaccination from its altruistic and moral
motivations of prevention. Without this ‘‘affective driver’’,
adherence to new vaccines is highly compromised by the fears
to which they may give rise in western societies where safety
concerns dominate and lead to demands for vaccines at ‘‘zero risk’’
[53]. This original result thus raises the question of the meaning of
vaccination in our modern societies where new individual
sensibilities coexist with changes in the circulation of pathogens.
More specifically, these results should provoke policy debate on
the role of the ethics of care in collective health [54].
4. Ecology of the vaccination campaign: general
practitioner information and involvement is mandatory
for the success of vaccine campaigns
Nearly all the persons who were vaccinated said they received
clear, unequivocal and explicit information from their regular
health care providers. On the other hand, those who refused the
vaccine mentioned multiple sources (health professionals, media,
friends and family) and very conflicting messages. They often
perceived that the recommendations were dissonant, contradicto-
ry, and indecisive.
More specifically, they stated that the medical establishment was
no longer the only legitimate stakeholder or speaker. The
population received direct messages from various institutional
players that fed a far-reaching controversy about the vaccine. This
controversy and multiplicity of messages damaged the bond of
trust that the interviewees said they had with their regular health
care providers. Indeed, this health crisis was seized as an
opportunity for the media and politicians to involve themselves
in health policy. As they grabbed the centre of the stage, they
delivered worrisome messages focused more on the potential risks
of vaccination than on its benefits because not balanced by
experience or true scientific information. Media studies and risk
research confirm this finding and highlight the sensational nature
of the coverage, which produced compelling news items to attract
large audiences but little information useful to the public in
deciding what they should do [31,50,55]. This competition
aroused wide public distrust and therefore sapped patients’
confidence in the information delivered by their practitioners
[8,31,56].
Nor did the medical establishment offer a consensus about the
indications for the A/H1N1 vaccine, as the refusers pointed out. A
previous study focused on health care practitioners indeed showed
that health care providers with inadequate knowledge about
pandemic influenza A/H1N1 and its vaccine recommended
vaccination less often than those who reported their knowledge
as adequate [20]. Excluded from the action aspect of prescribing
the vaccine, health care providers then in part offloaded
responsibility for its advisory aspects [57,58]. This abdication by
physicians, leaving patients to their own devices, was widely cited
by people who refused the vaccine.
Finally the interviews emphasized the contradiction the
respondents felt between, on the one hand, the resources
implemented by the health authorities (government communica-
tions and establishment of ad hoc vaccination centres), and the
reality of the epidemic on the other. The alarming public health
messages were not consistent with daily personal experience,
which did not confirm the threat [8,27]. This discrepancy between
message and reality in the French context calls to mind the
controversy over the HBV vaccine [59,60]. National health
authorities initiated universal HBV vaccination in the mid-1990s.
However, the emotions generated by the claim that HBV
vaccination might lead to multiple sclerosis resulted in a massive
rejection of the HBV vaccine. Beyond this resemblance, the gap
between the health authorities’ message and reality reminds us of a
larger set of health fears that have studded the recent history of
Western countries, including, as some of the interviewees
mentioned, the scandals about ‘‘mad cow’’ disease and GMO.
This specific dimension of the 2009 A/H1N1 pandemic is again
evidence of the national health authorities’ difficulties in
communicating about medical science and explaining vaccination
procedures to the general population [61].
5. Implications
On the whole, the behaviours during the 2009 pandemic
described above probably explain the low compliance rate for A/
H1N1 vaccination throughout most industrialized countries and
can be generalized to enable us to formulate recommendations to
improve the likelihood of success of a future pandemic
management plan.
Specifically, we have three main recommendations for improv-
ing adhesion to new vaccines:
(1) Patient education
It appears necessary to reinforce the education of patients about
their disease and its specific risks to convey accurate information
about the risk of the pandemic. This is in line with meta-analyses
which have shown that perceptions of risk are an important
predictor of uptake of vaccination against a variety of diseases [2].
We recommend that health authorities improve risk/benefit
communication and invest in the implementation of effective tools
for communicating vaccine risk/benefit ratios for future vaccina-
tion campaigns, emphasising the risks of not being vaccinated and
the benefits of vaccination, and explicitly acknowledging and
tackling safety concerns. As most of the refusers advocated the
efficacy of other prevention methods than vaccines, a target action
would be to convince these people that immunization provides
more protection than barrier measures. Because this study showed
that the accepters also based their decision on the collective
immunity aspect of the vaccine, explicitly intended to protect
others, we advocate that the message delivered should also
consider the altruistic principle of vaccination. It is important to
educate and engage citizens on the benefits of community
immunity.
(2) Health care provider involvement
Health care professionals are not impersonal participants in
individual and family illnesses, and it is essential not simply to treat
episodes of illness, but to build a relationship and provide
continuity of care [20]. Thus, the message about vaccines should
first and foremost be conveyed by local health care providers, with
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[27,45,47,62]. That message will be conveyed better if those
professionals are involved in implementing the immunization
[57,58], as shown by previous studies of H3N1 pandemics that
demonstrated both general practitioners’ unique skills in empow-
ering patients and translating national guidelines into public health
education and patients’ feelings that GPs’ are best at helping and
understanding them [63]. Primary health care providers should be
the first point of contact in the health care system to provide
better, comprehensive and continuing education during any
emerging health crisis. We emphasize that the success of a mass
vaccination campaign depends in large part on health care
practitioners advising the general public to be vaccinated.
(3) The message about the vaccine: It also seems crucial to
disseminate a clear and effective message about the safety of the
vaccine in terms of manufacturing and validation processes, safety
and efficacy [20,26,27,49,56]. In our modern societies where
health and the precautionary principle must be read together,
governments have a real obligation to communicate with the
public about the decisions to be made regarding health
interventions [64]. Because the media are an important source
of information for the public during infectious disease outbreaks, it
is important to provide it with regular and accurate information
from the very beginning, thereby preventing public misconcep-
tions and maintaining trust in the health authorities. We suggest
that constant updates on infection rates and vaccine safety should
be provided by health care authorities through the media to enable
viewers to reach conclusions about their own level of risk hand and
to develop a rational opinion on the vaccine’s risks and benefits.
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